The aptamer–siRNA conjugates: Reprogramming T Cells for Cancer Therapy
Year: 2015
Type: article
Abstract: Oligonucleotide agents combining the cell selectivity of aptamers with the molecular target specificity of siRNAs are likely to provide a new class of highly precise and safer therapeutics.
Source: Therapeutic Delivery
DOI: 10.4155/tde.14.92
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funder: National Cancer Institute
Award: G1133352505
OpenAlex ID: W2066198326
